ID   PC-9-GR-high
AC   CVCL_S706
DR   cancercelllines; CVCL_S706
DR   Cosmic; 1896429
DR   Wikidata; Q54938470
RX   PubMed=23542356;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=23542356; DOI=10.1158/0008-5472.CAN-12-4136;
RA   Shien K., Toyooka S., Yamamoto H., Soh J., Jida M., Thu K.L.,
RA   Hashida S., Maki Y., Ichihara E., Asano H., Tsukuda K., Takigawa N.,
RA   Kiura K., Gazdar A.F., Lam W.L., Miyoshi S.;
RT   "Acquired resistance to EGFR inhibitors is associated with a
RT   manifestation of stem cell-like properties in cancer cells.";
RL   Cancer Res. 73:3051-3061(2013).
//